Regarding "Management of Dermatologic Events Associated with the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin"

Saskia Ingen-Housz-Oro; Constance Thibault; Pierre Sohier; Nicolas Dupin

doi:10.1093/oncolo/oyac170

Regarding "Management of Dermatologic Events Associated with the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin"

Oncologist. 2022 Oct 1;27(10):e825-e826. doi: 10.1093/oncolo/oyac170.

Authors

Saskia Ingen-Housz-Oro^{1

2}, Constance Thibault³, Pierre Sohier⁴, Nicolas Dupin⁵

Affiliations

¹ Dermatology Department, Henri Mondor Hospital, AP-HP, Univ Paris-est Créteil EpidermE, Créteil, France.
² Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France.
³ Oncology Department, Georges Pompidou Hospital, AP-HP, Paris, France.
⁴ Pathology Department, Cochin Hospital, AP-HP, AP-HP.Centre-Université Paris Cité, Paris, France.
⁵ Dermatology Department, AP-HP, Cochin Hospital, Paris, France.

Abstract

This letter to the editor remarks on a recently published article about dermatologic events induced by enfortumab vedotin, comparing results from other similar studies.

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal / adverse effects
Carcinoma, Transitional Cell*
Humans
Immunoconjugates* / adverse effects
Nectins

Substances

Antibodies, Monoclonal
Immunoconjugates
Nectins
enfortumab vedotin